COVID-19 public transit precautions: Trade-offs between risk reduction and costs

Public transit has received scrutiny as a vector for spreading COVID-19 with much of the literature finding correlations between transit ridership and COVID-19 rates by assessing the role that transportation plays as a vector for human mobility in COVID-19 spread. However, most studies do not directly measure the risk of contracting COVID-19 inside the public transit vehicle. We fill a gap in the literature by comparing the risk and social costs across several modes of transportation. We develop a framework to estimate the spread of COVID-19 on transit using the bus system in Pittsburgh. We find that some trips have demand that exceed their COVID-19 passenger limit, where the driver must decide between: (1) leaving a passenger without a ride or (2) allowing them on the bus and increasing COVID-19 risk. We consider five alternatives for alleviating overcapacity: allow crowding, additional buses, longer buses as substitutes, Transportation Network Company (TNC) rides, or Autonomous Vehicles (AVs) for passed-by passengers. We use transit ridership and COVID-19 data from the spring of 2020 by combining transportation data and an epidemiological model of COVID-19 stochastically in a Monte Carlo Analysis. Our results show that 4% of county cases were contracted on the bus or from a bus rider, and a disproportionate amount (52%) were from overcapacity trips. The risk of contracting COVID-19 on the bus was low but worth mitigating. A cost-benefit analysis reveals that dispatching AVs or longer buses yield the lowest societal costs of $45 and $46 million, respectively compared to allowing crowding ($59 million).